Inoviq Ltd (IIQ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Inoviq Ltd (IIQ) has a cash flow conversion efficiency ratio of -0.098x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-2.18 Million ≈ $-1.54 Million USD) by net assets (AU$22.26 Million ≈ $15.75 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Inoviq Ltd - Cash Flow Conversion Efficiency Trend (1991–2025)
This chart illustrates how Inoviq Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Inoviq Ltd (IIQ) total liabilities for a breakdown of total debt and financial obligations.
Inoviq Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inoviq Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RenovoRx Inc
NASDAQ:RNXT
|
-0.281x |
|
HOYA Resort Hotel Group
TWO:2736
|
-0.014x |
|
Sakuma Exports Limited
NSE:SAKUMA
|
0.171x |
|
Australian Gold and Copper Ltd
AU:AGC
|
-0.013x |
|
Elektrocieplownia Bedzin
WAR:BDZ
|
0.159x |
|
Deliveroo Holdings PLC
LSE:ROO
|
0.239x |
|
Aurora Mobile Ltd
NASDAQ:JG
|
0.048x |
|
Picard Medical, Inc.
NYSE MKT:PMI
|
-0.818x |
Annual Cash Flow Conversion Efficiency for Inoviq Ltd (1991–2025)
The table below shows the annual cash flow conversion efficiency of Inoviq Ltd from 1991 to 2025. For the full company profile with market capitalisation and key ratios, see Inoviq Ltd (IIQ) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$16.71 Million ≈ $11.83 Million |
AU$-4.66 Million ≈ $-3.30 Million |
-0.279x | -28.97% |
| 2024-06-30 | AU$19.99 Million ≈ $14.14 Million |
AU$-4.32 Million ≈ $-3.06 Million |
-0.216x | +39.60% |
| 2023-06-30 | AU$19.62 Million ≈ $13.88 Million |
AU$-7.02 Million ≈ $-4.97 Million |
-0.358x | -67.16% |
| 2022-06-30 | AU$28.29 Million ≈ $20.02 Million |
AU$-6.06 Million ≈ $-4.29 Million |
-0.214x | -18.33% |
| 2021-06-30 | AU$29.06 Million ≈ $20.56 Million |
AU$-5.26 Million ≈ $-3.72 Million |
-0.181x | +53.79% |
| 2020-06-30 | AU$6.48 Million ≈ $4.58 Million |
AU$-2.54 Million ≈ $-1.79 Million |
-0.392x | -77.94% |
| 2019-06-30 | AU$7.13 Million ≈ $5.05 Million |
AU$-1.57 Million ≈ $-1.11 Million |
-0.220x | +87.34% |
| 2018-06-30 | AU$1.13 Million ≈ $799.89K |
AU$-1.97 Million ≈ $-1.39 Million |
-1.738x | +81.15% |
| 2017-06-30 | AU$257.94K ≈ $182.51K |
AU$-2.38 Million ≈ $-1.68 Million |
-9.221x | -33350.54% |
| 2016-06-30 | AU$2.83 Million ≈ $2.01 Million |
AU$-78.12K ≈ $-55.27K |
-0.028x | +61.75% |
| 2015-06-30 | AU$1.76 Million ≈ $1.24 Million |
AU$-126.65K ≈ $-89.62K |
-0.072x | -164.40% |
| 2014-06-30 | AU$888.13K ≈ $628.41K |
AU$99.38K ≈ $70.31K |
0.112x | +142.47% |
| 2013-06-30 | AU$2.92 Million ≈ $2.06 Million |
AU$-768.54K ≈ $-543.79K |
-0.263x | -465.92% |
| 2012-06-30 | AU$15.11 Million ≈ $10.69 Million |
AU$-703.24K ≈ $-497.59K |
-0.047x | +19.70% |
| 2011-06-30 | AU$26.60 Million ≈ $18.82 Million |
AU$-1.54 Million ≈ $-1.09 Million |
-0.058x | -42.54% |
| 2010-06-30 | AU$18.89 Million ≈ $13.37 Million |
AU$-768.35K ≈ $-543.66K |
-0.041x | +4.20% |
| 2009-06-30 | AU$19.03 Million ≈ $13.46 Million |
AU$-807.86K ≈ $-571.61K |
-0.042x | +65.11% |
| 2008-06-30 | AU$5.67 Million ≈ $4.01 Million |
AU$-689.60K ≈ $-487.93K |
-0.122x | +93.15% |
| 2007-06-30 | AU$2.04 Million ≈ $1.45 Million |
AU$-3.63 Million ≈ $-2.57 Million |
-1.777x | -264.88% |
| 2006-06-30 | AU$11.04 Million ≈ $7.81 Million |
AU$-5.38 Million ≈ $-3.80 Million |
-0.487x | -75.52% |
| 2005-06-30 | AU$16.88 Million ≈ $11.95 Million |
AU$-4.68 Million ≈ $-3.31 Million |
-0.277x | +19.00% |
| 2004-06-30 | AU$2.78 Million ≈ $1.97 Million |
AU$-952.64K ≈ $-674.05K |
-0.342x | +39.62% |
| 2003-06-30 | AU$2.48 Million ≈ $1.76 Million |
AU$-1.41 Million ≈ $-996.59K |
-0.567x | -127.34% |
| 2002-06-30 | AU$2.33 Million ≈ $1.65 Million |
AU$-580.86K ≈ $-411.00K |
-0.249x | -177.20% |
| 1999-06-30 | AU$9.09 Million ≈ $6.43 Million |
AU$-818.36K ≈ $-579.04K |
-0.090x | +0.39% |
| 1997-06-30 | AU$10.44 Million ≈ $7.39 Million |
AU$-943.60K ≈ $-667.65K |
-0.090x | -57.33% |
| 1996-06-30 | AU$10.31 Million ≈ $7.29 Million |
AU$-591.98K ≈ $-418.86K |
-0.057x | +6.84% |
| 1995-06-30 | AU$9.89 Million ≈ $7.00 Million |
AU$-610.00K ≈ $-431.61K |
-0.062x | +60.69% |
| 1994-06-30 | AU$9.72 Million ≈ $6.88 Million |
AU$-1.52 Million ≈ $-1.08 Million |
-0.157x | +82.55% |
| 1993-06-30 | AU$1.61 Million ≈ $1.14 Million |
AU$-1.45 Million ≈ $-1.02 Million |
-0.899x | +62.96% |
| 1992-06-30 | AU$286.00K ≈ $202.36K |
AU$-694.00K ≈ $-491.05K |
-2.427x | -128.19% |
| 1991-06-30 | AU$-23.00K ≈ $-16.27K |
AU$-198.00K ≈ $-140.10K |
8.609x | -- |
About Inoviq Ltd
INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. It offers non… Read more